A blood test for small molecules abnormally expressed in pancreatic cancer may be a promising route to early detection of the disease, researchers at The University of Texas M. D. Anderson Cancer Center report in the September edition of the journal Cancer Prevention Research.

A team of researchers, including several from UCSF, has demonstrated that a new method for detecting and quantifying protein biomarkers in body fluids may ultimately make it possible to screen multiple biomarkers in hundreds of patient samples, thus ensuring that only the strongest biomarker candidates will advance down the development pipeline.

Collaboration in prostate cancer translational research in Europe is not only vital to sustain the progress achieved in recent years but also to streamline current efforts between researchers and clinicians and avoid duplication or overlaps. This was amongst the goals of the two-day Prostate Cancer Translational Research in Europe (PCTRE) Meeting which opened today in Amsterdam, The Netherlands.

Three researchers from the Virginia Bioinformatics Institute (VBI) at Virginia Tech have developed and evaluated a new one-step bioanalytical approach that allows them to profile in detail complex cellular extracts of proteins. The method has allowed the scientists to look at how the levels of proteins change in breast cancer cells when they are treated with hormones or cancer drugs like tamoxifen.

A group led by Dr. Dan Theodorescu at the University of Virginia has identified a novel biomarker for metastatic bladder cancer. They report these findings in the February 2009 issue of The American Journal of Pathology.

Cincinnati scientists have identified a new biomarker that could help predict a person's risk of developing colon cancer and how aggressive it may become.

Researchers from Boston University School of Medicine (BUSM) have demonstrated that a recently discovered class of molecule called microRNA (miRNAs), regulate the gene expression changes in airway cells that occur with smoking and lung cancer.

Endocan, previously called endothelial cell specific molecule-1 (ESM-1), is over expressed in human tumors, and its serum levels are elevated in late-stage lung cancer and experimental tumor, as measured by enzyme-linked immunoassay or by immunohistochemistry.